Results from phase three clinical trials conducted by researchers from five different countries demonstrated the effectiveness of the drug semaglutide in reducing the body mass index in children suffering from obesity aged six to eleven years. Furthermore, the drug showed an acceptable safety profile.
Information on the progress of these trials was officially published in the scientific journal The New England Journal of Medicine.



